Fig. 7. Therapeutic efficacy of targeting PLK1 in pCMML.

A Daily cell counts of CMML MNC after transfection with either siNT or siPLK1. Representative western blot depicts validation of PLK1 knockdown from three experiments. Knockdown of PLK1 by qPCR was ≥90%. B Progenitor colony forming assay using CMML MNC with increasing doses of volasertib. Indicated p-value in panels A and B by two-tailed Student’s t test. C, D Histopathologic analysis with H&E staining and immunohistochemistry (IHC) of spleen (C) and BM (D) of murine patient-derived xenografts (PDX) after treatment with vehicle control or volasertib. Magnification is ×200 unless otherwise indicated. hCD45 is human CD45. E Representative flow cytometry of spleen, BM and PB of PDXs after treatment with vehicle control (left) or volasertib (right). The y-axis indicates hCD45 expression status while x-axis indicates murine CD45 (mCD45). Percentages indicate proportion of hCD45+ and mCD45- cells in the respective tissues. F Flow cytometry of proportion of hCD45+ cells in spleen, BM, and PB of PDX mice. Data are presented as mean ± SEM from nine mice. G, H Effect of vehicle versus volasertib treatment on PDX spleen size (G) and weight (H). Data in panel H are presented as mean ± SEM from seven mice treated with vehicle and eight treated with volasertib. Indicated p-value in panels F and H by two-tailed Student’s t test. Data in panels A and B are presented as mean ± SEM. The indicated n represents the number of biologic replicates. p-values are indicated with each comparison. Source data are provided as a Source Data file.